|
Mesothelioma Info
Guide
Mesothelioma of Pleura
Peritoneal Mesothelioma
Symptoms
Staging
Mesothelioma Lung Cancer
Pictures
Pleural
Effusion
Treatment
Options
Medical
Procedures
Drugs /
Medications
Information on Alimta
Find a
Doctor
Clinical Trials
Hospitals
Support
Coping Strategy
What to Do
Financial Recovery
Who Can Help
Mesothelioma Doctor Information
What Caused
Where was I
Exposed
Asbestos FAQ
Hazardous Jobs |
|
|
Information on Alimta Due to the revolutionary impact
Alimta (pemetrexed) has had on the Mesothelioma treatment, we have decided to dedicate a separate page that will follow all the
new developments regarding the trials and usage of Alimta.
Just click on one of the links below that will take you to the Alimta-related
article.
ALIMTA [ (pemetrexed) is now available on expanded access basis. ALIMTA will be available on an expanded access
use for people with malignant pleural mesothelioma, a cancer usually associated with exposure to asbestos. As of July 9, 2002
the Food and Drug Administration agreed to place ALIMTA in an expanded access program, which gives patients access to an agent
that isn't yet commercially available, although the sponsor is actively pursuing marketing approval. Eli Lilly is pursuing
approval of ALIMTA in combination with cisplatin for the treatment of malignant pleural mesothelioma, a disease that causes
tumors to grow in the linings of the lung, or pleura. Patients live an average of six to nine months following diagnosis. The
company said results of a Phase III trial showed that patients treated with ALIMTA and cisplatin combined lived longer and had
less pain and shortness of breath, than patients treated with cisplatin alone. In the trial, the most common side effect from
cisplatin and ALIMTA was a decrease in infection- fighting white blood cells. Under the expanded access program, ALIMTA will be
given free of charge to patients who meet medical eligibility requirements.
|
